SEARCH

SEARCH BY CITATION

References

  • Aoyama K, Matsubara K, Okada K, Fukushima S, Shimizu K, Yamaguchi S et al. (2000). N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test. J Neural Transm 107: 985995.
  • Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, Nusing RM et al. (2005). GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 115: 36343640.
  • Bieganowski P, Brenner C (2004). Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117: 495502.
  • Bieron K, Swies J, Kostka-Trabka E, Gryglewski RJ (1998). Thrombolytic and antiplatelet action of xanthinol nicotinate (Sadamin): possible mechanisms. J Physiol Pharmacol 49: 241249.
  • Chong ZZ, Lin SH, Maiese K (2002). Nicotinamide modulates mitochondrial membrane potential and cysteine protease activity during cerebral vascular endothelial cell injury. J Vasc Res 39: 131147.
  • Cylwik D, Mogielnicki A, Kramkowski K, Stokowski J, Buczko W (2004). Antithrombotic effect of L-arginine in hypertensive rats. J Physiol Pharmacol 55: 563574.
  • Declercq V, Yeganeh B, Moshtaghi-Kashanian GR, Khademi H, Bahadori B, Moghadasian MH (2005). Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice. J Cardiovasc Pharmacol 46: 1824.
  • Delaney J, Hodson MP, Thakkar H, Connor SC, Sweatman BC, Kenny SP et al. (2005). Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation. Arch Toxicol 79: 208223.
  • Dembinska-Kiec A, Korbut R, Bieron K, Kostka-Trabka E, Gryglewski RJ (1983). Beta-Pyridylcarbinol (Ronicol) releases a prostacyclin-like substance into arterial blood of patients with arteriosclerosis obliterans. Pharmacol Res Commun 15: 377385.
  • Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ (2001). Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108: 585590.
  • FitzGerald GA, Austin S, Egan K, Cheng Y, Pratico D (2000). Cyclo-oxygenase products and atherothrombosis. Ann Med 32 (Suppl 1): 2126.
  • Frein D, Schildknecht S, Bachschmid M, Ullrich V (2005). Redox regulation: a new challenge for pharmacology. Biochem Pharmacol 70: 811823.
  • Gebicki J, Sysa-Jedrzejowska A, Adamus J, Wozniacka A, Rybak M, Zielonka J (2003). 1-Methylnicotinamide: a potent anti-inflammatory agent of vitamin origin. Pol J Pharmacol 55: 109112.
  • Gosteli J (2005). Nicotinamide trials in diabetes intervention. Does a metabolite provide benefit Med Hypotheses 64: 10621063.
  • Grosser T, Fries S, FitzGerald GA (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116: 415.
  • Grudzinski S (1962). Preparation of N-methyl-2-pyridone-3-carboxamide. Roczniki Chemii 36: 17051708.
  • Gryglewski RJ (1980). Prostaglandins, platelets, and atherosclerosis. CRC Crit Rev Biochem 7: 291338.
  • Gryglewski RJ, Moncada S, Palmer RM (1986). Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br J Pharmacol 87: 685694.
  • Gryglewski RJ, Uracz W, Swies J, Chlopicki S, Marcinkiewicz E, Lomnicka M et al. (2001). Comparison of endothelial pleiotropic actions of angiotensin converting enzyme inhibitors and statins. Ann N Y Acad Sci 947: 229245.
  • Gupte SA, Arshad M, Viola S, Kaminski PM, Ungvari Z, Rabbani G et al. (2003). Pentose phosphate pathway coordinates multiple redox-controlled relaxing mechanisms in bovine coronary arteries. Am J Physiol Heart Circ Physiol 285: H2316H2326.
  • Hennan JK, Hong TT, Willens DE, Driscoll EM, Giboulot TA, Lucchesi BR (2002). Prevention of experimental carotid and coronary artery thrombosis by the glycoprotein IIb/IIIa receptor antagonist CRL42796. Br J Pharmacol 136: 927937.
  • Maiese K, Chong ZZ (2003). Nicotinamide: necessary nutrient emerges as a novel cytoprotectant for the brain. Trends Pharmacol Sci 24: 228232.
  • Maiza A, Waldek S, Ballardie FW, Daley-Yates PT (1992). Estimation of renal tubular secretion in man, in health and disease, using endogenous N-1-methylnicotinamide. Nephron 60: 1216.
  • Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W (2005). Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 93: 10691076.
  • Ohta S, Nakamuta M, Fukushima M, Kohjima M, Kotoh K, Enjoji M et al. (2005). Beraprost sodium, a prostacyclin (PGI) analogue, ameliorates concanavalin A-induced liver injury in mice. Liver Int 25: 10611068.
  • Pawlak R, Chabielska E, Buczko W (1996). Antithrombotic effect of enalapril, an angiotensin-converting enzyme inhibitor, on venous thrombosis in rats. Pol J Pharmacol 48: 117120.
  • Pike NB (2005). Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid. J Clin Invest 115: 34003403.
  • Pumpo R, Sarnelli G, Spinella A, Budillon G, Cuomo R (2001). The metabolism of nicotinamide in human liver cirrhosis: a study on N-methylnicotinamide and 2-pyridone-5-carboxamide production. Am J Gastroenterol 96: 11831187.
    Direct Link:
  • Satoh T, Ishikawa Y, Kataoka Y, Cui Y, Yanase H, Kato K et al. (1999). CNS-specific prostacyclin ligands as neuronal survival-promoting factors in the brain. Eur J Neurosci 11: 31153124.
  • Schumacher WA, Steinbacher TE, Heran CL, Megill JR, Durham SK (1993). Effects of antithrombotic drugs in a rat model of aspirin-insensitive arterial thrombosis. Thromb Haemost 69: 509514.
  • Shaw EN (1961). Quaternary pyridinium compounds. In: E Klingsberg (ed). Pyridine Its Derivatives. Interscience Publishers: New York, pp 131.
  • Swies J, Dabrowski L (1984). Release of disaggregatory prostanoids into circulation by nicotinic alcohol, nicotinic acid and nicotinamide. Pol J Pharmacol 36: 653657.
  • Tanimori S, Ohta T, Kirihata M (2002). An efficient chemical synthesis of nicotinamide riboside (NAR) and analogues. Bioorg Med Chem Lett 12: 11351137.
  • Ungerstedt JS, Heimersson K, Soderstrom T, Hansson M (2003). Nicotinamide inhibits endotoxin-induced monocyte tissue factor expression. J Thromb Haemost 1: 25542560.
  • Vivian VM, Chaloupka MM, Reynolds MS (1958). Some aspects of tryptophan metabolism in human subjects. I. Nitrogen balances, blood pyridine nucleotides and urinary excretion of N1-methylnicotinamide and N1-methyl-2-pyridone-5-carboxamide on a low-niacin diet. J Nutr 66: 587598.
  • Wise H, Jones RL (1996). Focus on prostacyclin and its novel mimetics. Trends Pharmacol Sci 17: 1721.
  • Wojewodzka-Zelezniakowicz M, Chabielska E, Mogielnicki A, Kramkowski K, Karp A, Opadczuk A et al. (2006). Antithrombotic effect of tissue and plasma type angiotensin converting enzyme inhibitors in experimental thrombosis in rats. J Physiol Pharmacol 57: 231245.
  • Wozniacka A, Wieczorkowska M, Gebicki J, Sysa-Jedrzejowska A (2005). Topical application of 1-methylnicotinamide in the treatment of rosacea: a pilot study. Clin Exp Dermatol 30: 632635.
  • Yan L, Otterness DM, Weinshilboum RM (1999). Human nicotinamide N-methyltransferase pharmacogenetics: gene sequence analysis and promoter characterization. Pharmacogenetics 9: 307316.